You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Cost reduction as a result of bortezomib vial sharing in the University Hospital Center ‘Mother Theresa’ Tirana
  1. Florjana Rustemi1,
  2. Ledjan Malaj2,
  3. Ela Hoti2,
  4. Enida Balla3
  1. 1 Department of Pharmacy, Albanian University, Tirana, Albania
  2. 2 Department of Pharmacy, University of Medicine, Tirana, Albania
  3. 3 Department of Pharmacy, University Hospital Center ‘Mother Theresa’ Tirana, Tirana, Albania
  1. Correspondence to PhD Student Florjana Rustemi, Department of Pharmacy, Albanian University, Tirana 1005, Albania; florjanarustemi{at}gmail.com

https://doi.org/10.1136/ejhpharm-2018-001676

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The costs associated with current and emerging therapies, as well as supportive care, are significant and pose a tremendous financial burden to both patients and healthcare system.1 This can be an obstacle for the treatment of patients and sometimes the decision related to the treatment of choice is made taking in consideration primarily the therapy costs and not the efficacy and clinical outcomes of the patients, especially in poor countries and low/middle-income countries, where the healthcare system financing is low and the budget allocated for drugs is not sufficient. The waste of drugs caused from the vial size also affects the financial costs of the treatment. Single-size vials of chemotherapy drugs may be an undernoticed source …

    View Full Text

    Footnotes

    • Contributors FR, the corresponding author, designed data collection tools, monitored data collection for the whole study, wrote the paper, analysed the data, and drafted and revised the paper. She is the guarantor. EB collected the data and revised the paper. LM and EH analysed the data and revised the paper.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.